The Shift Toward Regenerative Surgery
When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring and stiffness as part of the process. Over the last two decades, however, regenerative surgery has shifted the focus from replacement toward biology. Instead of asking only, “What can I put in this defect?” we are also asking, “How can I help the patient’s own tissue rebuild this?”
Our understanding of wound healing has become much more sophisticated. We now think in terms of the extracellular matrix, angiogenesis, and constructive remodeling rather than simply bringing tissue edges together and waiting for them to heal. [1,2] Biomaterials have evolved alongside that understanding. Instead of relying exclusively on traditional synthetic materials designed to remain separate from native tissue, we are increasingly working with matrices that allow tissue to infiltrate and vascularize the material as remodeling takes place. [3,4]
Patient expectations have evolved as well, with increasing demand for natural-looking results, smaller scars, faster recovery, and durable outcomes. This has encouraged surgeons to think more carefully about preserving healthy tissue and how our choices may affect healing.
To me, that is the real meaning of regenerative surgery. It is not a particular product category or a label attached to the newest technology. It is a shift in surgical philosophy toward preserving healthy tissue and supporting constructive remodeling, with the patient’s own biology playing a more active role in how we restore form and tissue.
Biomaterial Scaffolds and Tissue Integration
The shift toward regenerative surgery becomes especially tangible in the materials we use. Traditional synthetic implants are generally designed to remain in place permanently, with the body typically isolating them within a fibrous capsule. Biologically integrating materials operate differently, providing a framework that can allow the patient’s own cells and blood vessels to grow into the material as remodeling occurs. [5,6] I often explain the difference this way: a traditional synthetic implant is a tenant, while an integrating biomaterial is a scaffold for new construction.
Acellular dermal matrices, or ADMs, are one example. Derived from human or animal dermis processed to remove cellular components while preserving the extracellular matrix architecture, they provide structural support while allowing the patient’s cells and blood vessels to infiltrate the material. In my practice, ADMs are particularly valuable in prepectoral and revisionary breast reconstruction, where they can support an implant while preserving the pectoral muscle. [7,8] They also have applications in soft-tissue reinforcement and abdominal wall repair. Bioabsorbable scaffolds similarly provide temporary mechanical support before gradually resorbing as the patient’s tissue assumes that role.
Not every scaffold is appropriate for every patient or procedure. I consider its mechanical strength, remodeling or degradation timeline, biocompatibility, and manufacturing consistency, along with patient factors such as vascularity, smoking, previous radiation, and immune status. [9] Cost, clinical indication, and the maturity of the available evidence also matter. Conventional materials may still provide the most predictable option when immediate structural strength, reproducibility, or a longer clinical track record is the priority. Regenerative does not automatically mean superior. [10]
Tissue preservation is part of this same philosophy. Tissue-preserving approaches to breast augmentation are designed to minimize dissection and preserve native breast anatomy rather than routinely disrupting muscle and other supporting structures. [11,12] Long-term durability data are also still developing. [13]
Ultimately, the goal is not to use the newest or most biologically sophisticated material available. It is to choose the material and technique that best match the patient’s anatomy, biology, and clinical needs while preserving healthy tissue and supporting constructive remodeling.
Injectable Regenerative Biologics and Matrix-Based Therapies
The regenerative approach is also changing how we think about injectable treatments. Traditional dermal fillers, particularly hyaluronic acid fillers, primarily restore volume by occupying space within the tissue and attracting water. Collagen-based and extracellular matrix-derived injectables are designed around a different concept: rather than simply filling a space, the goal is to introduce a biological framework that can interact with the patient’s own tissue as remodeling occurs.
In principle, these materials can provide a matrix into which fibroblasts migrate, supporting collagen production and tissue integration over time. This may be particularly relevant for patients with true soft-tissue deficits, including age-related fat loss, contour irregularities, and significant volume depletion following major weight loss. These therapies may also offer an option for patients who do not have sufficient donor fat for autologous fat grafting or who would prefer to avoid the additional procedure required to harvest it.
Processed human adipose allografts are one example of where this category is heading. These products are designed to preserve components of the native fat matrix, offering an off-the-shelf approach to soft-tissue restoration without requiring the patient’s own fat to be harvested and transferred. The concept is compelling because the goal extends beyond simply occupying space: the material is intended to provide structural support while creating an environment that may allow biological integration and remodeling.
But this is also where we need to be precise about what we mean by “regenerative.” A biologically plausible mechanism is not the same as a demonstrated clinical outcome. These products are relatively new, and long-term peer-reviewed evidence regarding durability and reproducibility remains limited. Human-tissue products also raise important questions about sourcing, processing, consistency, and regulatory status. [14,15]
When I evaluate any injectable described as regenerative, I want to know not only how it is expected to interact with tissue, but whether the proposed benefit has been demonstrated consistently and safely in patients and whether those results persist over a meaningful period of time. The science behind matrix-based therapies is promising, but enthusiasm for the mechanism should not get ahead of the evidence.
Cellular Therapies: Promise, Evidence, and Regulatory Considerations
Some regenerative tools with the deepest clinical track record are also among the most familiar. Platelet-rich plasma, or PRP, and autologous fat grafting both use components derived from the patient’s own body, but they work differently, and the strength of the evidence varies depending on how they are used.
PRP concentrates a patient’s own platelets and the growth factors they release, including platelet-derived growth factor, transforming growth factor beta, and vascular endothelial growth factor. These signaling molecules are involved in angiogenesis, fibroblast activity, collagen synthesis, and wound healing. There is meaningful evidence supporting PRP in areas such as androgenetic hair loss [16,17,18], while the evidence for facial rejuvenation remains more mixed. In aesthetic practice, I view PRP as a useful adjunct in appropriately selected patients, although variation in preparation protocols can contribute to inconsistent outcomes.
Autologous fat grafting is another established technique whose significance has evolved alongside our understanding of tissue biology. [19,20] Traditionally viewed primarily as a way to restore volume and contour, grafted fat also carries adipose-derived cells and a bioactive matrix that may influence surrounding tissue. [21,22,23] Clinically, I have seen fat grafting soften scars, improve the quality of skin and soft tissue, and help rehabilitate damaged or previously irradiated tissue. However, recognizing the regenerative potential of adipose tissue does not mean every fat-transfer procedure should be characterized as “stem cell therapy.”
Exosomes represent a much newer and more uncertain frontier. These extracellular vesicles carry proteins, lipids, and nucleic acids involved in cell-to-cell communication and, in theory, could allow regenerative signals to be delivered without transplanting living cells. [24] However, clinical evidence in aesthetic surgery remains early. Promising preclinical work and small human studies exist, but large, well-controlled trials demonstrating durable aesthetic benefits are still lacking, and differences in source cells, culture conditions, isolation methods, dosing, storage, and manufacturing make standardization difficult. [25,26]
The regulatory landscape is equally important. Exosome-based products marketed for treating disease or modifying tissue function generally require FDA approval, and the FDA has issued safety communications concerning unapproved products marketed as exosome therapies. [27,28] Scientific interest in extracellular vesicles should not be mistaken for regulatory approval or established clinical efficacy.
For me, exosomes illustrate both the promise and the responsibility that come with regenerative medicine. A compelling biological mechanism can justify serious investigation, but it cannot substitute for clinical proof. We should be excited about where the science may lead while remaining disciplined about what we can responsibly claim today.
Scientific Challenges and Areas of Active Investigation
As regenerative technologies continue to develop, one of the biggest challenges is deciding when an innovation is ready to move from scientific promise into clinical practice. I approach that decision as I would any new surgical technology: the more novel the claim, the stronger the evidence should be.
I place greater value on prospective, peer-reviewed studies, particularly when findings have been reproduced independently, than on manufacturer-sponsored materials or early reports without meaningful follow-up. I also look closely at what a study is actually measuring. Laboratory markers or imaging findings may be scientifically interesting, but what matters clinically is whether patients experience meaningful improvements in healing, function, tissue quality, complications, durability, or quality of life.
Safety has to come before novelty. Before incorporating a new regenerative technology into practice, I want to understand its regulatory status, how consistently it is manufactured or processed, what complications have been reported, and whether other surgeons can reproduce the results. [29] I also consider whether the benefit is substantial enough to justify the added cost, complexity, or uncertainty.
Long-term outcomes and patient selection are equally important. A promising short-term response is not enough without understanding what happens months or years later. Vascularity, smoking, previous radiation, immune status, tissue quality, age, and other clinical factors can also influence healing and remodeling, meaning a therapy that performs well in one setting may not behave the same way in another.
Progress will also require collaboration among surgeons, scientists, engineers, developers, and translational researchers so that clinical adoption does not outpace scientific validation. Ultimately, responsible adoption requires credible peer-reviewed evidence, appropriate regulation, reproducible results, benefits that justify the risks and costs, and outcomes that persist long enough to matter to the patient. Regenerative surgery should be measured by better patient outcomes, not by how quickly new technologies reach the market.
The Future of Regenerative Aesthetic Surgery
Over the next five to ten years, meaningful advances in regenerative plastic surgery will come from technologies that work more precisely with the patient’s own biology. I am particularly interested in smarter biomaterial scaffolds that support predictable remodeling, advances in fat grafting and tissue engineering, and tissue-preserving techniques that minimize disruption of healthy anatomy.
I am also interested in the continued development of extracellular vesicle and exosome science, with an important distinction between the potential of the science and the products being marketed today. The ability to influence cellular signaling without transplanting living cells is compelling, but better standardization, stronger clinical trials, and clearer regulatory pathways are needed before responsible use in routine aesthetic practice.
More broadly, I expect regenerative surgery to become increasingly integrated into surgical planning rather than remaining a separate category of treatment. The future is likely to combine better biomaterials, biologic therapies, and tissue-preserving techniques tailored to the patient and clinical problem, creating a better biological environment for healing while preserving healthy tissue whenever possible.
At the same time, some areas of regenerative medicine are being marketed ahead of the evidence. [30] Terms such as “stem cell therapy” and “exosome therapy,” along with injectables promoted as producing permanent regeneration, can imply a degree of clinical certainty that the current evidence does not always support. A compelling mechanism, before-and-after image, or patient testimonial is not enough to establish that a treatment is safe, reproducible, and durable.
Regenerative medicine is one of the most promising frontiers in plastic surgery, which is why it deserves rigorous evaluation. “Regenerative” is a scientific standard to be met, not a marketing word to be trusted. Maintaining that distinction can move us toward surgery that is biologically sound, evidence-based, and ultimately more meaningful to the patient.
Author Bio
